John Mhoon, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,629 of the $5,165 with a category attached, or 89.6%. It is spread thinly across 40 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations.
Across 225 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$978
- Johnson & Johnson$646
- AbbVie$578
- Sumitomo Pharma America, Inc.$501
- Pfizer$384
- Dendreon Pharmaceuticals LLC$250
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,62990%
- Education$53510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 37 | $978 |
| Johnson & Johnson | 19 | $646 |
| AbbVie(2 entities) | 37 | $578 |
| Sumitomo Pharma America, Inc. | 14 | $501 |
| Pfizer | 18 | $384 |
| Dendreon Pharmaceuticals LLC | 10 | $250 |
| Boston Scientific | 13 | $202 |
| Bayer | 9 | $185 |
| AstraZeneca | 5 | $141 |
| Urogen Pharma, Inc. | 6 | $136 |
| Sun Pharmaceutical Industries Inc. | 5 | $136 |
| Accord Healthcare, Inc. | 5 | $113 |
| Tolmar, Inc. | 6 | $104 |
| Merck | 4 | $102 |
| Progenics Pharmaceuticals, Inc. | 3 | $77 |
| Verity Pharmaceuticals Inc. | 3 | $55 |
| Myriad Genetic Laboratories, Inc. | 3 | $46 |
| Convatec Inc. | 1 | $45 |
| Endo Pharmaceuticals Inc. | 3 | $41 |
| Ferring Pharmaceuticals Inc. | 3 | $40 |
| Coloplast | 2 | $39 |
| Smith+Nephew | 1 | $32 |
| 180 Medical, Inc. | 1 | $28 |
| Rochester Medical Corporation | 1 | $27 |
| Ambu Inc. | 1 | $26 |
| Procept Biorobotics Corporation | 1 | $24 |
| Laborie Medical Technologies Corp. | 1 | $23 |
| Novartis | 1 | $22 |
| Novo Nordisk | 1 | $21 |
| Immunitybio, Inc. | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Tolmar Pharmaceuticals, Inc. | 1 | $17 |
| EDAP Technomed Inc | 1 | $17 |
| ABC Home Medical Supply, Inc. | 1 | $15 |
| Innovation Technologies Inc | 1 | $14 |
| Tempus AI, Inc | 1 | $14 |
| Amgen | 1 | $14 |
| Cook Medical LLC | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEMTESA$105
How this compares
$5,165 in reported general payments places this provider in the 80th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 45 | $699,958 |
| XtandiEnzalutamide | 37 | $525,607 |
| GemtesaVibegron | 294 | $210,376 |
| MyrbetriqMirabegron | 260 | $175,579 |
| OrgovyxRelugolix | 17 | $42,476 |
| Tamsulosin Hcl | 1,071 | $15,883 |
| Potassium Citrate ErPotassium Citrate | 141 | $14,118 |
| Mirabegron ErMirabegron | 19 | $9,635 |
| Silodosin | 87 | $6,355 |
| Finasteride | 281 | $3,484 |
| Allopurinol | 125 | $3,355 |
| Testosterone | 27 | $2,157 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 61 | $1,659 |
| Desmopressin Acetate | 32 | $1,251 |
| Dutasteride | 40 | $711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $978 | $701,186297 claims |
| Johnson & JohnsonErleada | $646 | $699,95845 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $501 | $252,852311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 153 urology providers in Oregon.
Other urology in Salem
- Bradley WarnerSalem$8K
- Philip RosenSalem$3K
- Bryan MehlhaffSpringfield$1M
- Lance MarrPortland$323K
- Matt AshleyBend$212K
- da David JiangPortland$65K
- Kim ThaiMedford$57K
- Kevin KrughoffSpringfield$54K
- Kyle GillisClackamas$51K
- Amir PatelPortland$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.